title: [Current status of gestagen administration. 2. Gestagen therapy in the area of reproduction].
abstract: The spectrum of progestin therapy has changed and expanded during the last few years. 1. The drug-therapy of choice in endometriosis is the medication of progestins for at least six months, for instance ethinyl-testosterone. If a patient wants additional children the "more gentle" dydrogesterone should be considered. 2. In the treatment of dysmenorrhea combination pills should be given, sequentials should be avoided. In the case of incompatibility of estrogens or in danger of oversuppression syndrome dydrogesterone should be applicated. 3. Dysfunctional bleedings should lead to an intense search for their cause. The treatment consists in an estrogen-progestin combination for 9 days and in cyclic continuation of this therapy for at least a further three months. In the case of hemorrhagic diathesis progestin treatment should be continued. 4. Cyclic adequate progestins have proofed to be successful in handling of hirsutism. The choice of the preparation depends on the patient's wish for children. 5. The progestin test is still the first step in diagnosis of amenorrhea. 6. Progestin therapy is indicated in progressive endometrial carcinoma. Some medical centres treat carcinoma of the mamma successfully with progestins. 7. Nowadays fast and early hormonal pregnancy tests are available. The progestin-pregnancy-test is limited to cases of premenopause. 8. The so-called short luteum phase has received considerable attention as a possible cause of infertility. In these cases a substitutional therapy of progestins should follow. Clomiphene or HCG-therapy is advisable. In short luteum phase and premenstrual spottings potent progestins should be given. 9. High dosage of progestins are in common use in the treatment of abortus imminens. 10. Combination pills and sequentials are widely used, the possible methods of a pure progestin contraception are: minipills, three-month-injections, implanted silastic capsules with progestional compounds, progestin impregnated intrauterine devices, vaginal silastic rings impregnated with progestional compounds. 11. Carcinogenesis of progestins was not detectable. 12. Some progestins are teratogenic.
mesh_terms: D000033:Abortion, Threatened / Q000188:drug therapy; D003267:Contraception; D003277:Contraceptives, Oral, Combined / Q000627:therapeutic use; D003279:Contraceptives, Oral, Sequential / Q000627:therapeutic use; D003281:Contraceptives, Postcoital / Q000627:therapeutic use; D003338:Corpus Luteum / Q000187:drug effects; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy; D006801:Humans; D011247:Pregnancy; D045167:Progesterone Congeners / Q000627:therapeutic use; D011372:Progestins / Q000627:therapeutic use*
chemical_list: D003277:Contraceptives, Oral, Combined; D003279:Contraceptives, Oral, Sequential; D003281:Contraceptives, Postcoital; D004967:Estrogens; D045167:Progesterone Congeners; D011372:Progestins
vernacular_title: Zum aktuellen Stand der Anwendung von Gestagenen. 2. Gestagen-Therapie auf dem Gebiet der Reproduktion